Sodium-dependent phosphate transport protein 2B
(Redirected from NaPi2b)
| SLC34A2 | |||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Aliases | SLC34A2, NAPI-3B, NAPI-IIb, NPTIIb, solute carrier family 34 member 2, PULAM | ||||||||||||||||||||||||||||||||||||||||||||||||||
| External IDs | OMIM: 604217; MGI: 1342284; HomoloGene: 2297; GeneCards: SLC34A2; OMA:SLC34A2 - orthologs | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Sodium-dependent phosphate transport protein 2B (NaPi2b) is a protein that in humans is encoded by the SLC34A2 gene.[5][6][7]
Clinical significance
[edit]Sodium-dependent phosphate transport protein 2b (NaPi2b) is a tumor-associated antigen.[8]
upifitamab rilsodotin, an antibody-drug conjugate (ADC) targeting NaPi2b, was evaluated in Phase 3 clinical trials for recurrent platinum-sensitive ovarian cancer. The trials were, however, terminated in September of 2023 by the sponsor.[9]
See also
[edit]References
[edit]- 1 2 3 GRCh38: Ensembl release 89: ENSG00000157765 – Ensembl, May 2017
- 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000029188 – Ensembl, May 2017
- ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ↑ Feild JA, Zhang L, Brun KA, Brooks DP, Edwards RM (May 1999). "Cloning and functional characterization of a sodium-dependent phosphate transporter expressed in human lung and small intestine". Biochemical and Biophysical Research Communications. 258 (3): 578–582. doi:10.1006/bbrc.1999.0666. PMID 10329428.
- ↑ Xu H, Bai L, Collins JF, Ghishan FK (December 1999). "Molecular cloning, functional characterization, tissue distribution, and chromosomal localization of a human, small intestinal sodium-phosphate (Na+-Pi) transporter (SLC34A2)". Genomics. 62 (2): 281–284. doi:10.1006/geno.1999.6009. PMID 10610722.
- ↑ "Entrez Gene: SLC34A2 solute carrier family 34 (sodium phosphate), member 2".
- ↑ Yin BW, Kiyamova R, Chua R, Caballero OL, Gout I, Gryshkova V, et al. (February 2008). "Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas". Cancer Immunity. 8: 3. PMC 2935786. PMID 18251464.
- ↑ Clinical trial number NCT05329545 for "Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)." at ClinicalTrials.gov
Further reading
[edit]- Xu H, Collins JF, Bai L, Kiela PR, Ghishan FK (March 2001). "Regulation of the human sodium-phosphate cotransporter NaP(i)-IIb gene promoter by epidermal growth factor". American Journal of Physiology. Cell Physiology. 280 (3): C628–C636. doi:10.1152/ajpcell.2001.280.3.C628. PMID 11171583. S2CID 7439508.
- Segawa H, Kaneko I, Takahashi A, Kuwahata M, Ito M, Ohkido I, et al. (May 2002). "Growth-related renal type II Na/Pi cotransporter". The Journal of Biological Chemistry. 277 (22): 19665–19672. doi:10.1074/jbc.M200943200. PMID 11880379.
- Xu H, Uno JK, Inouye M, Collins JF, Ghishan FK (February 2005). "NF1 transcriptional factor(s) is required for basal promoter activation of the human intestinal NaPi-IIb cotransporter gene". American Journal of Physiology. Gastrointestinal and Liver Physiology. 288 (2): G175–G181. doi:10.1152/ajpgi.00396.2004. PMID 15458926. S2CID 14194207.
- Otsuki T, Ota T, Nishikawa T, Hayashi K, Suzuki Y, Yamamoto J, et al. (2007). "Signal sequence and keyword trap in silico for selection of full-length human cDNAs encoding secretion or membrane proteins from oligo-capped cDNA libraries". DNA Research. 12 (2): 117–126. doi:10.1093/dnares/12.2.117. PMID 16303743.
- Kimura K, Wakamatsu A, Suzuki Y, Ota T, Nishikawa T, Yamashita R, et al. (January 2006). "Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes". Genome Research. 16 (1): 55–65. doi:10.1101/gr.4039406. PMC 1356129. PMID 16344560.
- Corut A, Senyigit A, Ugur SA, Altin S, Ozcelik U, Calisir H, et al. (October 2006). "Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis". American Journal of Human Genetics. 79 (4): 650–656. doi:10.1086/508263. PMC 1592565. PMID 16960801.
- Izumi S, Miyazawa H, Ishii K, Uchiyama B, Ishida T, Tanaka S, et al. (February 2007). "Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis". American Journal of Respiratory and Critical Care Medicine. 175 (3): 263–268. doi:10.1164/rccm.200609-1274OC. PMID 17095743.
 | This membrane protein–related article is a stub. You can help Wikipedia by adding missing information. |